Wegovy Total Scripts Hit 446,000/Week with 40.5% Obesity GLP-1 Market Share — Injectable Strength Holds Despite First Pill Decline
Even with the first weekly Wegovy pill prescription decline since launch (~143K to ~137K week-ending May 8), the total Wegovy franchise (injectable + pill) climbed 1.3% week-over-week to approximately 446,000 prescriptions per the Fierce Pharma IQVIA tracker. Market share in the US obesity GLP-1 segment ticked up 0.1 percentage points to 40.5%. The injectable Wegovy 2.4 mg and Wegovy HD 7.2 mg formulations remain Novo's commercial anchor; the pill is the growth narrative. The 1.3% w/w injectable Wegovy growth aligns with Novo's H2 2026 international expansion plans and the EU approval expected before year-end. The data also confirms Zepbound (tirzepatide for obesity) continues to grow share faster than Wegovy on an absolute volume basis — the head-to-head dynamic that Cantor Fitzgerald and Barclays both cited in their May 5 LLY price target raises.